Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Research
Biotech
Clinical Data
Venture Capital
Deals
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Cell & Gene Therapy
COVID-19
Emerging Biopharma
Podcasts
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Subscribe
What are you searching for?
Enclose phrases in quotes. Use a + to require a term in results and - to exclude terms.
Example: +water -Europe
Subscribe
Research
Biotech
Clinical Data
Venture Capital
Deals
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Cell & Gene Therapy
COVID-19
Emerging Biopharma
Podcasts
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
prostate cancer
Biotech
Janssen can't conjure up patients for ESSA prostate cancer trial
After a fruitless search for patients with a specific type of prostate cancer, Janssen is suspending a phase 1 trial being conducted with ESSA Pharma.
Annalee Armstrong
Oct 31, 2022 10:20am
ESMO: A peak at Pfizer's EZH2 inhibitor flashes hope for some
Sep 11, 2022 6:00am
China's Jemincare nabs $650M biobucks pact with Genentech
Aug 18, 2022 7:08am
FDA clears AI software for spotting prostate cancer in MRI scans
Aug 8, 2022 11:01am
Amgen takes BiTEs out of pipeline, dropping BCMA, PSMA assets
Aug 5, 2022 7:50am
Exact Sciences sells Oncotype prostate cancer test for $30M
Aug 3, 2022 11:37am
